Drug Trial Radar · NCT05727878
Trial to Evaluate Safety and Efficacy of KPI-012 Ophthalmic Solution in Participants With PCED
Last checked: Nov 19, 2026Latest source record: Oct 22, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
103
Actual
Start
Feb 7, 2023
Primary completion
Sep 29, 2025
Study completion Oct 19, 2025
Sponsor
- Lead sponsor
- Combangio, IncIndustry
- Sponsor type
- Industry
- Collaborators
- Kala Pharmaceuticals, Inc.
- First posted
- Feb 14, 2023
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to investigate the safety and efficacy of KPI-012 compared to vehicle in participants who have a documented clinical diagnosis of PCED.
Conditions
- Persistent Corneal Epithelial Defect
Interventions
KPI-012Drug
KPI-012 is a secretome product composed of biologically active components secreted from human bone marrow-derived mesenchymal stem cells
KPI-012 VehicleDrug
KPI-012 formulation with no active drug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Response statusTime frame: Day 56
Locations
46 sites in 3 countries. Site status is shown where the registry gives one.
Principal Investigator
Dothan, Alabama
Principal Investigator
Irvine, California
Principal Investigator
La Jolla, California
Principal Investigator
Loma Linda, California
Principal Investigator
Los Angeles, California
Principal Investigator
Los Angeles, California
Principal Investigator
Pasadena, California
Principal Investigator
Rancho Cordova, California
Principal Investigator
Aurora, Colorado
Principal Investigator
Fort Collins, Colorado
Principal Investigator
Littleton, Colorado
Principal Investigator
Miami, Florida
Principal Investigator
Miami, Florida
Principal Investigator
Orange City, Florida
Principal Investigator
Atlanta, Georgia
Principal Investigator
Carmel, Indiana
Principal Investigator
Indianapolis, Indiana
Principal Investigator
Louisville, Kentucky
Principal Investigator
Boston, Massachusetts
Principal Investigator
Boston, Massachusetts
Principal Investigator
Chesterfield, Missouri
Principal Investigator
Kansas City, Missouri
Principal Investigator
Kansas City, Missouri
Principal Investigator
St Louis, Missouri
Principal Investigator
Palisades Park, New Jersey
Principal Investigator
New York, New York
Principal Investigator
Rockville Centre, New York
Principal investigator
Durham, North Carolina
Principal Investigator
Garner, North Carolina
Principal Investigator
Powell, Ohio
Principal Investigator
Philadelphia, Pennsylvania
Principal Investigator
Pittsburgh, Pennsylvania
Principal Investigator
Rapid City, South Dakota
Principal Investigator
Memphis, Tennessee
Principal Investigator
Nashville, Tennessee
Principal Investigator
Austin, Texas
Principal Investigator
Austin, Texas
Principal Investigator
Houston, Texas
Principal Investigator
San Antonio, Texas
Principal Investigator
Norfolk, Virginia
Showing 40 of 46 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.